ArticleJTO clinical and research reports2025

Retreatment With Nivolumab and Ipilimumab in Pleural Mesothelioma Following Disease Progression After a Durable Response: Case Series.

Illaa Smesseim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.